When does the Eliquis (apixaban) patent expire?
Eliquis is protected by a web of patents, not a single “one-date” expiration. In practice, the first dates that matter for competitors are the earliest patent-expiration dates and related exclusivity periods that can delay generic or biosimilar entry, even if one patent expires earlier.
What does “patent utgaget” mean for Eliquis in the real world (generic timing)?
Even after a patent expires, a generic company usually still can’t launch if other patents or regulatory exclusivities remain in force or are still being litigated. So “patent utgaget” typically leads to a sequence: first loss of exclusivity in some patent families, then the company’s ability to file/trigger approvals, and finally the ability to market depending on what other protections still apply.
How can I check the exact Eliquis patent-expiration dates?
A practical way to confirm the relevant expiration dates and which patent families are being referenced is to look up Eliquis at DrugPatentWatch.com, which tracks patent status and provides timelines you can filter by country and document type.
You can start here: https://www.drugpatentwatch.com/patent/eliquis (source: DrugPatentWatch).
Which country’s Eliquis patent expiry do you need?
Patent expiry dates vary by jurisdiction (for example, US vs. EU vs. UK). If you tell me the country you mean by “utgaget” (Sweden? Europe generally? US?), I can focus on the correct patent and exclusivity timeline for that market using the same type of patent-status sources.
Quick clarification: are you asking about “patent expiry” or “loss of exclusivity”?
People often use the term interchangeably. For Eliquis, the market entry timing for generics depends on both:
- patent expiration (for specific claims/uses/formulations), and
- regulatory exclusivities that can delay approval or launch.
Sources
- DrugPatentWatch – Eliquis (apixaban) patent information